Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 8/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.31 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613554 | 0.82 | PPARG (0.36) | GSK3BIKBKB | |
| SCHEMBL613309 | 0.80 | IKBKB (0.40) | GSK3BIKBKBMKNK2 | |
| SCHEMBL614197 | 0.78 | IKBKB (0.41) | GSK3BIKBKB | |
| SCHEMBL490588 | 0.74 | IKBKB (0.57) | GSK3BIKBKB | |
| SCHEMBL612154 | 0.74 | IKBKB (0.53) | GSK3BIKBKB | |
| SCHEMBL20572261 | 0.72 | IKBKB (0.47) | GSK3BIKBKB | |
| SCHEMBL611765 | 0.71 | CDC7 (0.50) | GSK3BMKNK2 | |
| SCHEMBL614072 | 0.71 | PTGS2 (0.44) | — | |
| SCHEMBL27524639 | 0.69 | ALDH1A1 (0.41) | GSK3BIKBKB | |
| SCHEMBL16246374 | 0.69 | GSK3B (0.42) | GSK3BIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | GSK3B 656/4885IKBKB 993/4885MKNK2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.